89bio Inc.

3 trials 2 recruiting Commercial sponsor

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

2 Recruiting

1 Completed trials

12 Countries active

2 Unique IMPs

100% Results reported

Phase III

Oversight events:

1 corrective measure across 1 trial

View oversight register →

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

BIO89-100 3 SIMVASTATIN 1

All trials

3 total

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-fibrosis) Recruiting

2023-509912-27-00 Phase III 10 countries BIO89-100
Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH (ENLIGHTEN-Cirrhosis) Recruiting

2023-510395-31-00 Phase III 9 countries BIO89-100
A Ph3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia: The ENTRUST study Ended

2023-503576-25-00 Phase III 11 countries BIO89-100; SIMVASTATIN

Showing 1–3 of 3 trials

← All sponsors A–Z